New Medications Highlight 2014 Rheumatoid Arthritis News

Article

A look at the top rheumatoid arthritis stories on HCPLive for 2014.

It has been a big year in the treatment of diagnosis of rheumatoid arthritis and all throughout 2014 we have covered this condition from a variety of angles. Here is a look at our top 10 stories from the year.

Rheumatoid Arthritis Drug Linked to Increased Likelihood of Shingles

A drug designed to treat patients with rheumatoid arthritis could also make them more susceptible to shingles, according to the results of a recent study.

http://www.hcplive.com/articles/Rheumatoid-Arthritis-Drug-Linked-to-Possible-Shingles-Link

FDA Approves New Drug for Rheumatoid Arthritis

The US Food and Drug Administration recently announced its approval of a new medication for the treatment of rheumatoid arthritis.

http://www.hcplive.com/product-news/FDA-Approves-New-Drug-for-Rheumatoid-Arthritis

Researchers Find ‘Cure’ for Rheumatoid Arthritis in Mice

European researchers may have found a key to unlocking a cure for rheumatoid arthritis

http://www.hcplive.com/articles/Researchers-Find-Cure-for-Rheumatoid-Arthritis-in-Mice

White Blood Cells Have Role in Rheumatoid Arthritis

Rheumatoid arthritis may develop from a specific type of white blood cell, according to research published in Cell Reports.

http://www.hcplive.com/articles/White-Blood-Cells-Have-Role-in-Rheumatoid-Arthritis

Women Using IUDs at Greater Risk for Rheumatoid Arthritis

Intrauterine devices (IUDs) may contribute to an increased risk of the development of rheumatoid arthritis (RA) in women, according to a presentation at the American College of Rheumatology Annual Meeting held November 14-19 in Boston.

http://www.hcplive.com/conferences/acr-2014/Women-Using-IUDs-at-Greater-Risk-for-Rheumatoid-Arthritis

Costs for Rheumatoid Arthritis Treatments Could Drop According to Study

Patients being treated for rheumatoid arthritis could see their healthcare costs take a noticeable drop according to the results of a recent study.

http://www.hcplive.com/articles/Costs-for-Rheumatoid-Arthritis-Treatments-Could-Drop-According-to-Study

Hydroxychloroquine Reduces Risk of Cardiovascular Events in Rheumatoid Arthritis

The anti-arthritis drug hydroxychloroquine dramatically reduces the risk of cardiovascular morbidity and mortality in the disease, according to research presented at the 2014 meeting of the American College of Rheumatology.

http://www.hcplive.com/conferences/acr-2014/Hydroxychloroquine-Reduces-Risk-of-Cardiovascular-Events-in-Rheumatoid-Arthritis

Treating to Target Reduces Rheumatoid Arthritis Mortality

Adjusting treatment to maintain tight control of disease-related disability reduces mortality in rheumatoid arthritis, according to new research presented at the 2014 annual meeting of the American College of Rheumatology.

http://www.hcplive.com/conferences/acr-2014/Treating-to-Target-Reduces-Rheumatoid-Arthritis-Mortality

New NIH Network Will Support Development of Novel Treatments for Rheumatoid Arthritis and Lupus

The National Institutes of Health (NIH) announced today that it has “awarded grants to 11 research groups across the United States to establish the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network.”

http://www.hcplive.com/articles/New-NIH-Network-Will-Support-Development-of-Novel-Treatments-for-Rheumatoid-Arthritis-and-Lupus

Zoster Vaccination in Patients with Rheumatoid Arthritis: Time to Change the Recommendation?

Administration of the varicella zoster vaccine is safe in patients with rheumatoid arthritis (RA) or other rheumatic conditions who are taking biologic disease-modifying anti-rheumatic drugs (DMARDs), according to a new study presented at the meeting of the American College of Rheumatology.

http://www.hcplive.com/conferences/acr-2014/Zoster-Vaccination-in-Patients-with-Rheumatoid-Arthritis-Time-to-Change-the-Recommendation

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
© 2024 MJH Life Sciences

All rights reserved.